Emmaus Life Sciences Receives Endari® Marketing Authorization from the Bahrain NHRA
TORRANCE, Calif., May 31, 2023 /PRNewswire/ — Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease treatment, announced today that it has received a Medicine Registration Certificate (DRN-10164/23) from the Bahrain National Health Regulatory Authority (NHRA) granting marketing authorization for the commercial distribution and sale of Endari® in the Kingdom of Bahrain.
Related news for (EMMA)
- Emmaus Life Sciences Reports Quarterly Financial Results
- Emmaus Life Sciences Receives FDA Approval for Endari® Label Enhancements
- Emmaus Life Sciences Reports Quarterly Financial Results
- Emmaus Life Sciences Reports 2024 Financial Results
- Emmaus Life Sciences Reports Improved Quarterly Financial Results